Idelalisib

Catalog No.S2226 Synonyms: CAL-101, GS-1101

For research use only.

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

Idelalisib  Chemical Structure

CAS No. 870281-82-6

Selleck's Idelalisib has been cited by 231 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Targets
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
In vitro

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. [1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. [2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 M4fEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\EUXNQ M2r5ZWlEPTB;MkCuOEDPxE1? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7OUO1Nkc,OjV7OUmzOVI9N2F-
CLL PBMCs NETlOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNSG1UVw>? NWnBSHdPUUN3ME2yMlkhdk1? NYLVd3NXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVczPjdpPkK1PVE4OjZ5PD;hQi=>
U266 NFvYSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELEXYw1OCEQvF2= M2H0d|Q5KGh? Ml\uO|kvPSViaX7obYJqfGmxbjDyZZRm M{exdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5N|MzLz5{NUOzPVM{OjxxYU6=
K562 NG\Te4hHfW6ldHnvckBCe3OjeR?= NUHlcoVROSEQvF2= NHvIUWo{KGh? NWraZ4dxUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NWqzZ2t5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
K562 Ml;BSpVv[3Srb36gRZN{[Xl? MXOxJO69VQ>? MU[zJIg> MlfyTY5pcWKrdHnvckBw\iCSN{DTOmsheGixc4Doc5J6dGG2aX;u NEnTNVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
K562 MX;GeY5kfGmxbjDBd5NigQ>? M4m0SVEh|ryP MXmzJIg> M2nDVmlvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= NH;kXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
K562 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHaeZYyKM7:TR?= MoXZO|IhcA>? MXTJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36= NWK4dYlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell M1\adGZ2dmO2aX;uJGF{e2G7 M{fXOVEh|ryP M1HFclMhcA>? MUjJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NVXub5QzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell NHjxS|hHfW6ldHnvckBCe3OjeR?= M2nhOVEh|ryP M1LvXFMhcA>? Mnf5TY5pcWKrdHnvckBw\iCSN{DTOmsheGixc4Doc5J6dGG2aX;u M1e1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell NGPzR2lHfW6ldHnvckBCe3OjeR?= MX:xJO69VQ>? NYrEeGl{OyCq NUnkN41MUW6qaXLpeIlwdiCxZjDHV2s{KHCqb4PwbI9zgWyjdHnvci=> M3vQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell M1LlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnQW5EyKM7:TR?= MWGzJIg> Ml:wV5VxeHKnc4Ppc44hd2ZicmLORUB{gW62aHXzbZM> NIi3XGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
Microglia M2nycmZ2dmO2aX;uJGF{e2G7 MknlOUDPxE1? M1XS[FExKGh? MoHwSG1UVw>? NVjBRmdjTGWlcnXhd4Uhd2ZiVF7GZUB{\WO{ZYTpc44h\nKxbTDMVHMue3SrbYXsZZRm\CBicEGxNO61TDlzMFGvSFkyOEFibXnjdo9odGmj NWP4RYs2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlU3QDRpPkK0OlI2Pjh2PD;hQi=>
Primary CLL cell NWLKWZpSTnWwY4Tpc44hSXO|YYm= M333WlEh|ryP Ml34NVUhdWmw Moj1SG1UVw>? M2KzZWJtd2OtczDCR3IucW6mdXPl[EBNS1BzIIPldolv\S13IHHjeIl3[XSrb36= NYfYdYNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkzOzNpPkK0NFA6OjN|PD;hQi=>
JEKO-1 NETiSpNHfW6ldHnvckBCe3OjeR?= NVqwcZpEOSEQvF2= NX;EUXJkPzJiaB?= M4PhfWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF? NUjsTJh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFE2PDFpPkKzN|QyPTRzPD;hQi=>
Granta-519 MlHqSpVv[3Srb36gRZN{[Xl? NWT5e5Z3OSEQvF2= M4\mU|IhcA>? MlXUTY5pcWKrdHnvckBw\iCDa4SoeFMxQClicHjvd5Bpd3K7bHH0bY9v MkPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NEG1OFEoRjJ|M{SxOVQyRC:jPh?=
Granta-519 M4TLd2Z2dmO2aX;uJGF{e2G7 M1\uN|Eh|ryP NXTnZnRpOiCq MXnJcohq[mm2aX;uJI9nKEGtdDjzOFc{MSCyaH;zdIhwenmuYYTpc44> MlXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NEG1OFEoRjJ|M{SxOVQyRC:jPh?=
JEKO-1 M3[0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNEDPxE1? NUjEOJJ[PzJiaB?= MUnJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gd4xq\2i2bIm= MoXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NEG1OFEoRjJ|M{SxOVQyRC:jPh?=
JEKO-1 NYCwZY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnWbVc2KM7:TR?= M17lPFczKGh? NUK3bVd{\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>? NXHkblRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O|YzOjBpPkKzOlc3OjJyPD;hQi=>
MAVER-1 NXjBeFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn3c2JuPSEQvF2= MXW3NkBp MVzkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
MINO M2WxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4S2I2KM7:TR?= NXXUVHpqPzJiaB?= MX;kc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
SP53 M37JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHkb5cxNjFizszN M2TBXlczKGh? MYXkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
HH M1HYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PnVlExKM7:TR?= MX23NkBp NITIem1FVVOR NIj2XW9KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IIPsbYdpfGy7 MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
Myla MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEDPxE1? Mmj2O|IhcA>? MWLEUXNQ M4Dnd4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NWPqSnlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFE6PTlpPkKyPFAyQTV7PD;hQi=>
SR786 MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;kNVAh|ryP NUDqXFJ2PzJiaB?= MY\EUXNQ MUPkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| MkX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
HuT78 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILHSpQyOCEQvF2= MXW3NkBp MWLEUXNQ MmTB[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
MJ NX7LT45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES0TZAyOCEQvF2= NXfCNVZIPzJiaB?= M{DiVmROW09? Ml;o[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= M1y3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
DERL7 NUH1TZRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojONVAh|ryP MljzO|IhcA>? NEHsfo1FVVOR M2PyfIRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
L1236 NEe1WJVHfW6ldHnvckBCe3OjeR?= NITMfZQyOCEQvF2= M4PER|IhcA>? MU\Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F-
L428 MnP2SpVv[3Srb36gRZN{[Xl? NI\kOWIyOCEQvF2= MnPLNkBp MUfJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? M3vCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
L591 NX3CZpkyTnWwY4Tpc44hSXO|YYm= M1PPfFExKM7:TR?= NYixT4FlOiCq MXzJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F-
KMH-2 NFi2PYZHfW6ldHnvckBCe3OjeR?= M1jE[VExKM7:TR?= MXiyJIg> NUDvWoxmUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NWHPXGdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L1236 M2PMNGZ2dmO2aX;uJGF{e2G7 MUG1JO69VQ>? M1HVNVI1KGh? MX\CcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1 NWnjUGY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L591 M1PYe2Z2dmO2aX;uJGF{e2G7 M1jNV|Uh|ryP NHzWcHkzPCCq Ml\SRoxw[2u|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=> Mly5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O|coRjJ{MkGwPFc4RC:jPh?=
L1236 NHnyZoJCeG:ydH;zbZMhSXO|YYm= NVy0eYZLPSEQvF2= NGHXN2IzPCCq Ml7tTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F-
L591 NVL3flR6SXCxcITvd4l{KEG|c3H5 M4PGdlUh|ryP NGLsUWYzPCCq M13IZmlv\HWldHnvckBw\iCjcH;weI9{cXN? NHzNe3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
U-87MG NWHXSlNLTnWwY4Tpc44hSXO|YYm= NXXkd3UyOTByIH7N MUOyOEBp M4O5ZmROW09? NWr5RpBrUW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
SW1783 MkHsSpVv[3Srb36gRZN{[Xl? M2fJPFExOCCwTR?= NGHudZIzPCCq NW\NdHl2TE2VTx?= NVe0THRxUW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25? M17sT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
U-87MG MnTySpVv[3Srb36gRZN{[Xl? MkHxOUDPxE1? NEf3fGwzPCCq M{jZXGROW09? NITSVXlKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? NFzrOnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO|k3ODl:L3G+
SW1783 NYLXPYhQTnWwY4Tpc44hSXO|YYm= NXS4S2VFPSEQvF2= MYOyOEBp MojwSG1UVw>? M4THXWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6 NWj5NVRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=>
U-373MG NW\oe3dHTnWwY4Tpc44hSXO|YYm= MVG1JO69VQ>? MX[yOEBp NUW2N5R4TE2VTx?= NWX3e|Q5UW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? M322c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
SK-MG3 M2XiUWZ2dmO2aX;uJGF{e2G7 NF\CSoI2KM7:TR?= MWWyOEBp MWPEUXNQ MnS4TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> NYPOWWFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=>
SU-DHL-5 MWHGeY5kfGmxbjDBd5NigQ>? M3e3NlEh|ryP M1jsflI1KGh? MlzoSG1UVw>? MX;JcoR2[3Srb36gc4Yh[XCxcITvd4l{ M1rFfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUW5OlA3Lz5{MEm1PVYxPjxxYU6=
WSU-NHL Ml\tSpVv[3Srb36gRZN{[Xl? NVn5PXlYOSEQvF2= MYGyOEBp MnX4SG1UVw>? NX7iZoM3UW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl3OU[wOkc,OjB7NUm2NFY9N2F-
CCRF-SB NXHJUW1OTnWwY4Tpc44hSXO|YYm= NGn1O5UyKM7:TR?= M1SzW|I1KGh? MYHEUXNQ MULJcoR2[3Srb36gc4Yh[XCxcITvd4l{ M3n6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUW5OlA3Lz5{MEm1PVYxPjxxYU6=
INA-6 MoTGSpVv[3Srb36gRZN{[Xl? M{nQ[FUh|ryP MWC2JIg> M4jnXWlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiYX7kJGVTUyCyYYToe4F6 NX;LfGF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NFUyPThpPkKwOVA2OTV6PD;hQi=>
LB M122ZWZ2dmO2aX;uJGF{e2G7 NG\xcmY2KM7:TR?= MXy2JIg> NX2yfXZnUW6qaXLpeIlwdiCxZjDQTVRMN0GtdDDhcoQhTVKNIIDheIh4[Xl? NFro[nI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWwOVE2QCd-MkC1NFUyPTh:L3G+
B-cells M4nIfGZ2dmO2aX;uJIF{e2G7 M3TOT2lvcGmkaYTpc44hd2ZiUFmzT4RmdHSjIHnuJGIu[2WubIOgZpkheHKxbHnm[ZJifGmxbjDhd5NigSxiSVO1NEA:KDBwMEC2NUDPxE1w MoXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7MkS2PFgoRjJ{OUK0Olg5RC:jPh?=
MOLM14 NEnTOYZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVSzJIRigXN? M1HmVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyIE2gN{43KM7:TT6= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
MV4-11 MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MXGzJIRigXN? NHHhfIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFYvOyEQvF2u NIjVWHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
Jurkat NIHuPIRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4Xj[VMh\GG7cx?= MmTWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTBiPTC3Mlkh|ryPLh?= NHnUXm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
Loucy M2LDTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Ml\FN{Bl[Xm| MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxdXP5JINmdGy|IHHmeIVzKDNiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxKD1iOD60JO69VS5? NVi4eGVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
MOLT4 NEnMUnRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkXyN{Bl[Xm| MnvTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEGwMlYh|ryPLh?= NUnvdYVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
insect cells NF;JRW9HfW6ldHnvckBie3OjeR?= NYLSUmVWUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBJcXNvdHHn[4VlKFCLM1vnZY1u[SCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{NCCLQ{WwJF0hOC5yOEmg{txONg>? M3q5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
SUDHL6 NIXXVmZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M32z[FczKGi{cx?= MnHHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVVTIUFYh[2WubIOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxKD1iMD6xNVc3KM7:TT6= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh2NkS1NUc,Ojd6NE[0OVE9N2F-
insect cells M4fnTGZ2dmO2aX;uJIF{e2G7 MnfoTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDIbZMufGGpZ3XkJHBKO0ukZYThJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOsJGlEPTBiPTCwMlU3PSEQvF2u M{Pz[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
SU-DHL4 MoDxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Ml;2O|IhcHK| MnLqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVT3ETGw1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOkDPxE1w NYHrZ24xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
Pfeiffer NU\DfYw2SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3\ZdVczKGi{cx?= MoL0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSZnXp[oZmeiClZXzsd{Bu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTC2Mlgh|ryPLh?= NVjX[VJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
KARPAS422 M4rhe2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MVm3NkBpenN? MnX3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQWLQRXM1OjJiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gPE4yKM7:TT6= Mn7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
Sf21 MnztSpVv[3Srb36gZZN{[Xl? NWP6WllWOzBibXnudy=> MnnSTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKFCLM1ugdFEyOGKndHGveY51[WepZXSgdoVkd22kaX7hcpQh\nWubDDs[Y5ofGhiaIXtZY4heDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIGDJVFIwSVSSIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSB|Lkeg{txONg>? NYHsUVV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNFY6QTFpPkK4NVA3QTlzPD;hQi=>
Sf21 M1m4Z2Z2dmO2aX;uJIF{e2G7 MVGzNEBucW6| MmW3TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKFCLM1ugdFEyOGKndHGveY51[WepZXSgdoVkd22kaX7hcpQh\nWubDDs[Y5ofGhiaIXtZY4heDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIGDJVFIwSVSSIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSB|Lkeg{txONg>? NG\3fJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEGwOlk6OSd-MkixNFY6QTF:L3G+
RPMI8266 M4LxdWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoCwO|IhcHK| NUXwTpdMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ4NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMEW0PUDPxE1w MoXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MkW2NFEoRjJ6M{K1OlAyRC:jPh?=
Raji Mnj1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MnfpO|IhcHK| MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKjanmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEC5PVUh|ryPLh?= NFLs[Fk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOyOVYxOSd-MkizNlU3ODF:L3G+
KARPAS422 NH[0TIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2rjUWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtCWlCDU{SyNkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC54ODFOwG0v MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|NUiwOUc,Ojh6M{W4NFU9N2F-
Pfeiffer NYfYXFdQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEnaZ5FIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBR\mWrZn\ldkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC55NDFOwG0v MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|NUiwOUc,Ojh6M{W4NFU9N2F-
Saos-2 Ml3adWhVWyCjc4PhfS=> M{LZ[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= NFLaWVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MkjwdWhVWyCjc4PhfS=> M2fYbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz NXHKU2N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MXXxTHRUKGG|c3H5 NHfNdpNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= M{TDXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MVnxTHRUKGG|c3H5 M2rHUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= M37qU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 Mm\zdWhVWyCjc4PhfS=> M3T2XZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NXroS|hkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NV\4Wo9ueUiWUzDhd5NigQ>? NG\seYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= MnvlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC M{TmbZFJXFNiYYPzZZk> MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NE\DW249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M{HSdZFJXFNiYYPzZZk> NGnGblRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> M3TPbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 Mki2dWhVWyCjc4PhfS=> Mn3BdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| M{nyblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SUDHL6 MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3np[lczKGi{cx?= MnHlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVVTIUFYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlY2KM7:TT6= M1TmRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
RPMI8226 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NH7EZVc4OiCqcoO= Mny2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUUF3JPFIzPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gOU41QSEQvF2u MoL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5N|YoRjJ7NUO0PVM3RC:jPh?=
Raji NULBSGpYSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGqwO5A4OiCqcoO= M1;LOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUnHqbUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iOT65OUDPxE1w M4HLW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
SU-DHL6 MkP4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV60NoNsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1VvRFjMOkBk\WyuczDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yNEKg{txONg>? NF:0bnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[wNVk6OSd-Mkm2NFE6QTF:L3G+
MOLM13 NHfMR2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlWxO|IhcHK| M37COWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1QVE1zMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW|Y3XueEBie3OjeTygS2k2OCB;IEGuO{DPxE1w NV;ab3hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=>
MOLM14 NF23NGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXTabHBDPzJiaILz MX\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZZN{[XluIFfJOVAhRSB4LkSg{txONg>? NX:3[WdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=>
MOLM14 NIWwT3NCdnSrdIXtc5Ih[XO|YYm= MV:xNFAhdWdxa3e= NYHq[VROOTRiZHH5dy=> M1riXWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMECgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCmYXnsfUB3cWFiZ3H2ZYdmKGSxc3XkJIZweiBzNDDkZZl{KGGwZDDt[YF{fXKnZDDkZYltgSCmdYLpcoch[2:vcH;1coQh\G:|aX7nJJJmdGG2aY\lJJRwKGOxboTyc4w> NUHwSo5qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=>
MOLM14 NHXhdmhCdnSrdIXtc5Ih[XO|YYm= NFOwUpAyODBibXevb4c> NUnBelkzOTRiZHH5dy=> MUDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVQh[2WubIOgfIVvd2e{YX\0[YQhcW5iboWvcpUhdW:3c3WgZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIHHwc5B1d3OrczDheEAyODBibXevb4ctKHCxIHHkcYlvcXO2ZYLl[EBl[WmueTD2bYEh\2G4YXflJIRwe2WmIH\vdkAyPCCmYYnzJIFv\CCvZXHzeZJm\CCmYXnsfUBlfXKrbnegZ49ueG:3bnSg[I9{cW6pIHL5JHRWVkWOIHLhd4VlKGG|c3H5 M4f2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO|IyLz5|MEC1N|czOTxxYU6=
MOLM14 NUXvWJk{SW62aYT1cY9zKGG|c3H5 NIDsN|IyODBibXevb4c> MV[xOEBl[Xm| NVT5W4d5SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUW9NVTF2IHPlcIx{KHinbn;ndoFnfGWmIHnuJI52N263IH3veZNmKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhfHWvb4KgdJJwdGmoZYLheIlwdiBzMECgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCmYXnsfUB3cWFiZ3H2ZYdmKGSxc3XkJIZweiBzNDDkZZl{KGGwZDDt[YF{fXKnZDDkZYltgSCmdYLpcoch[2:vcH;1coQh\G:|aX7nJIJ6KEurLU[3JIxi[mWubHnu[{Bj[XOnZDDpcY12dm:q M2fEd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO|IyLz5|MEC1N|czOTxxYU6=
Assay
Methods Test Index PMID
Western blot Akt(T308) / PDK1(S241) / GSK-3β(S9) ; p-FoxO3a / FoxO3a ; Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax ; Cleaved caspase 3 / Cleaved caspase 9 ; p-AKT / AKT ; p-p65 ; Bim / Bcl-xl / Bid / Mcl-1 ; PUMA / p53 27342398 30224718 28008149
Growth inhibition assay Cell viability ; Cell viability 30224718 28008149

Protocol (from reference)

Kinase Assay:[2]
  • PI3K assay:

    PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.

Cell Research:[2]
  • Cell lines: CLL B cells or healthy volunteer T cells or NK cells
  • Concentrations: 0.01-100 μM
  • Incubation Time: 48 hours
  • Method: MTT assays are performed to determine cytotoxicity. 1 × 105 cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm2 flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+20%PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 415.42
Formula

C22H18FN7O

CAS No. 870281-82-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03582098 Completed Drug: Idelalisib|Drug: Rituximab Chronic Lymphocytic Leukaemia Gilead Sciences September 12 2018 --
NCT03151057 Active not recruiting Drug: Idelalisib 100 MG|Drug: Placebo Oral Tablet B Cells-Tumors|B Cell Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Gilead Sciences July 31 2018 Phase 1
NCT03568929 Completed Drug: Idelalisib Follicular Non-Hodgkin''s Lymphoma Refractory Gilead Sciences May 25 2018 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What is the recommended dose of CAL-101 and the route of administration for mouse studies?

Answer:
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

Tags: buy Idelalisib | Idelalisib supplier | purchase Idelalisib | Idelalisib cost | Idelalisib manufacturer | order Idelalisib | Idelalisib distributor